4/2
08:24 am
guts
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes [Yahoo! Finance]
Medium
Report
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes [Yahoo! Finance]
4/2
08:00 am
guts
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
Low
Report
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
4/1
07:06 am
guts
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
4/1
07:00 am
guts
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/1
06:08 am
guts
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs [Yahoo! Finance]
High
Report
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs [Yahoo! Finance]
4/1
06:00 am
guts
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Low
Report
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
3/12
02:06 pm
guts
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Neutral
Report
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
3/12
08:52 am
guts
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity [Yahoo! Fi
High
Report
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity [Yahoo! Fi
3/12
08:38 am
guts
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
High
Report
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
2/28
08:38 am
guts
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
Low
Report
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
2/27
07:08 am
guts
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $26.00 price target on the stock.
Medium
Report
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $26.00 price target on the stock.
2/27
07:08 am
guts
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $18.00 price target on the stock.
Medium
Report
Fractyl Health, Inc. (NASDAQ: GUTS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $18.00 price target on the stock.
2/20
08:38 am
guts
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Low
Report
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials